Skip header and navigation

Refine By

21 records – page 1 of 3.

Allogeneic bone marrow transplantation for leukemia in Europe: regional differences. Report from the Leukemia Working party of the European Group for Bone Marrow Transplantation.

https://arctichealth.org/en/permalink/ahliterature25241
Source
Bone Marrow Transplant. 1990 Mar;5(3):159-65
Publication Type
Article
Date
Mar-1990
Author
A. Gratwohl
J. Hermans
A J Barrett
P. Ernst
F. Frassoni
G. Gahrton
A. Granena
H J Kolb
H G Prentice
J P Vernant
Author Affiliation
Department of Internal Medicine, University Hospital Basel, Switzerland.
Source
Bone Marrow Transplant. 1990 Mar;5(3):159-65
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Bone Marrow Transplantation - mortality - statistics & numerical data
Chi-Square Distribution
Child
Child, Preschool
Comparative Study
Europe - epidemiology
Female
Graft vs Host Disease - prevention & control
Humans
Infant
Leukemia, Lymphocytic, Acute - mortality - surgery
Leukemia, Myelocytic, Acute - mortality - surgery
Leukemia, Myeloid, Chronic - mortality - surgery
Male
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Retrospective Studies
Survival Rate
Abstract
The results of 1904 allogeneic HLA identical sibling donor bone marrow transplants performed in 52 European centers between 1979 and 1986 and reported to the EBMT leukemia registry were analysed by geographical location of the transplant. Patients were grouped into six regions: United Kingdom, Nordic Group, Benelux, France, Central Europe and Southern Europe. There were significant differences between these regions with respect to patient population and outcome. The relative proportion of the three major disease categories, stage and subtype of the diseases, graft-versus-host disease prevention methods, donor recipient sex combinations, age of the patient, year of the transplant and the time intervals from diagnosis to transplant, from diagnosis to first complete remission for acute leukemia and the time from first complete remission to the transplant varied from region to region. The analysis of outcome parameters showed a significant difference in relapse incidence from region to region. This influence of region was confirmed in a multivariate analysis and was independent of the other factors known to affect outcome. Leukemia-free survival and transplant-related mortality were not different. The reasons for these differences could not be explained by the data in the registry. We conclude that regional factors must be considered when bone marrow transplant data are compared and we postulate that pretransplant factors probably affect outcome more than was previously realized.
PubMed ID
2331536 View in PubMed
Less detail

Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry.

https://arctichealth.org/en/permalink/ahliterature25880
Source
Hematol Oncol. 1988 Apr-Jun;6(2):181-6
Publication Type
Article
Author
G. Gahrton
S. Tura
M. Flesch
A. Gratwohl
P. Gravett
A. Lindeberg
G. Lucarelli
M. Michallet
J. Reiffers
O. Ringdén
Author Affiliation
Department of Medicine, Huddinge Hospital, Sweden.
Source
Hematol Oncol. 1988 Apr-Jun;6(2):181-6
Language
English
Publication Type
Article
Keywords
Bone Marrow Transplantation
Follow-Up Studies
Graft vs Host Disease
Humans
Multiple Myeloma - therapy
Registries
Sweden
Transplantation, Homologous
Abstract
Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone-marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.
PubMed ID
3292376 View in PubMed
Less detail

Allogeneic bone marrow transplantation in multiple myeloma.

https://arctichealth.org/en/permalink/ahliterature22787
Source
Br J Haematol. 1996 Feb;92(2):251-4
Publication Type
Article
Date
Feb-1996

Allogeneic bone marrow transplantation in patients with multiple myeloma.

https://arctichealth.org/en/permalink/ahliterature25655
Source
Eur J Haematol Suppl. 1989;51:182-5
Publication Type
Article
Date
1989
Author
G. Gahrton
S. Tura
C. Belanger
M. Cavo
B. Chapvis
A. Ferrant
M. Flesch
M. Gore
A. Gratwohl
P J Gravett
Source
Eur J Haematol Suppl. 1989;51:182-5
Date
1989
Language
English
Publication Type
Article
Keywords
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Marrow Transplantation - adverse effects - mortality
Combined Modality Therapy
Evaluation Studies
Female
Humans
Male
Middle Aged
Multicenter Studies
Multiple Myeloma - mortality - surgery - therapy
Survival Rate
Sweden - epidemiology
Transplantation, Homologous
Whole-Body Irradiation
Abstract
50 patients with a median age of 41 years (range 29-54) underwent allogenic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treatment. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34%. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears to be a promising method for treatment of certain patients with multiple myeloma.
PubMed ID
2697589 View in PubMed
Less detail

Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival.

https://arctichealth.org/en/permalink/ahliterature25379
Source
Clin Transpl. 1990;:175-87
Publication Type
Article
Date
1990
Author
O. Ringdén
J. Aschan
L. Boström
G. Dahllöf
J. Tollemar
T. Paulin
G. Gahrton
C G Groth
S. Klaesson
R. Lindquist
Author Affiliation
Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden.
Source
Clin Transpl. 1990;:175-87
Date
1990
Language
English
Publication Type
Article
Keywords
Adult
Bone Marrow Transplantation - immunology
Female
Follow-Up Studies
Graft vs Host Disease
Histocompatibility testing
Humans
Leukemia - surgery
Male
Metabolic Diseases - surgery
Research Support, Non-U.S. Gov't
Retrospective Studies
Sweden
Tissue Donors
Transplantation, Homologous
Abstract
At Huddinge Hospital 275 patients underwent allogeneic bone marrow transplantation. Among children in first remission of acute leukemia or chronic phase CML (early leukemia), with HLA-identical marrow the 8-year leukemia-free survival was 77%. This was better than 38% in children undergoing transplantation in second to fourth remission (p less than 0.0009). In adults with early leukemia, the 8-year leukemia-free survival was 47% compared to 21% for intermediate-risk adults (p = 0.007). Among 25 patients with severe aplastic anemia receiving marrow from HLA-identical siblings, the actuarial 10-year survival was 78%. In 14 patients with various metabolic disorders, of whom half received marrow from HLA-mismatched donors, the actuarial 7-year survival was 71%. Forty-three patients were given marrow from HLA-mismatched donors and had an increased incidence of acute graft-versus-host disease (GvHD) and death due to GvHD compared to recipients of HLA-identical bone marrow. The major causes of death among our patients were relapse of leukemia, death due to GvHD, cytomegalovirus (CMV) pneumonitis, bacterial infection and invasive fungal infections. By preventing GvHD with T-cell depletion or methotrexate (MTX) combined with cyclosporine (CsA) acute GvHD decreased, but the incidence of relapse increased compared to patients treated with MTX or CsA alone. This resulted in improved survival in patients older than 30 years, but a nonsignificant decrease in leukemia-free survival in younger patients. There was an association between herpes virus immunity in the recipient and GvHD. CMV pneumonitis increased following GvHD and decreased in patients treated with MTX combined with CsA. Invasive fungal infections may be treated or prevented using amphotericin B encapsulated in liposomes with few side effects.
PubMed ID
2103143 View in PubMed
Less detail

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.

https://arctichealth.org/en/permalink/ahliterature25502
Source
Eur J Haematol. 1989 Jul;43(1):54-62
Publication Type
Article
Date
Jul-1989
Author
A. Osterborg
A. Ahre
M. Björkholm
M. Björeman
G. Brenning
G. Gahrton
H. Gyllenhammar
B. Johansson
G. Juliusson
M. Järnmark
Author Affiliation
Radiumhemmet, Department of Biostatistics, Karolinska Hospital, Stockholm, Sweden.
Source
Eur J Haematol. 1989 Jul;43(1):54-62
Date
Jul-1989
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic use
Carmustine - administration & dosage
Clinical Trials
Comparative Study
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Humans
Melphalan - administration & dosage
Middle Aged
Multiple Myeloma - drug therapy
Prednisone - administration & dosage
Prospective Studies
Random Allocation
Research Support, Non-U.S. Gov't
Sweden
Vincristine - administration & dosage
Abstract
86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44). The treatment gropus were well comparable with regard to major prognostic factors. There was no statistically significant difference in the response rates, 52% (VMCP/VBAP) vs 61% (MP); in the response duration times, median 19 months vs 22 months, or in the survival times, median 24 months vs 28 months. However, survival of patients older than 65 years was significantly shorter in the VMCP/VBAP group (median 15 months) compared to the MP group (median 23 months) (p = 0.03). No significant difference in non-hematological or hematological toxicity was noted. The study further supports the notion that MP therapy should be used as primary standard treatment for patients with multiple myeloma.
PubMed ID
2670605 View in PubMed
Less detail

Bone marrow transplantation for aplastic anemia and acute leukemia at Huddinge Hospital.

https://arctichealth.org/en/permalink/ahliterature27256
Source
Scand J Urol Nephrol Suppl. 1981;64:238-45
Publication Type
Article
Date
1981
Author
O. Ringdén
B. Blom
H. Collste
G. Gahrton
C G Groth
G. Grimfors
A. Heimdahl
G. Lundgren
B. Lönnqvist,
E. Möller
P. Pihlstedt
Source
Scand J Urol Nephrol Suppl. 1981;64:238-45
Date
1981
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Anemia, Aplastic - epidemiology - mortality - therapy
Bone Marrow Transplantation
Child
Child, Preschool
Female
Graft Rejection
Graft vs Host Reaction - drug effects
Humans
Leukemia - epidemiology - therapy
Leukemia, Myelocytic, Acute - epidemiology - mortality - therapy
Male
Middle Aged
Prednisolone - therapeutic use
Research Support, Non-U.S. Gov't
Sweden
Abstract
Eight patients with aplastic anemia were transplanted with marrow from HLA-identical donors. Two patient rejected their grafts and died while 5 patients (71%) show no ill effects 3 months, 10 months, and more than 1, 2 and 4 years after the transplantation. Three of the patients who received unirradiated donor buffy coat after transplantation developed chronic graft-versus-host disease (GVHD) which, however, resolved following treatment with Prednisolone and Azathioprine. One patient with end-stage acute myeloid leukemia, who was transplanted with marrow from an identical twin, died 6 days after the transplantation of bleedings and sepsis. Eight patients with acute non-lymphoblastic leukemia (ANL) were transplanted, while in remission, with marrow from HLA-identical siblings. One patient died of interstitial pneumonia 3 months after transplantation, while another patient recovered from GVHD of the gut at 5 months after the transplantation. Seven out of 8 patients with ANL (88%) are home and well between 2 and 12 months after the transplantation.
PubMed ID
6755685 View in PubMed
Less detail

Cancer research in the European community--report from a meeting in Stockholm in 1995.

https://arctichealth.org/en/permalink/ahliterature22568
Source
Eur J Cancer. 1996 Jul;32A(8):1300-2
Publication Type
Conference/Meeting Material
Date
Jul-1996
Author
G. Gahrton
A. Graessman
F. Meunier
M. Schitt
J J Van Dongen
S S Baig
Author Affiliation
Department of Medicine, Karolinska Institute at Huddinge Hospital, Sweden.
Source
Eur J Cancer. 1996 Jul;32A(8):1300-2
Date
Jul-1996
Language
English
Publication Type
Conference/Meeting Material
Keywords
Animals
Europe
Humans
Neoplasms
Research
Sweden
PubMed ID
8924322 View in PubMed
Less detail

21 records – page 1 of 3.